Wu‐Chou Su
YOU?
Author Swipe
View article: Stratifying lung adenocarcinoma risk with multi-ancestry polygenic risk scores in East Asian never-smokers
Stratifying lung adenocarcinoma risk with multi-ancestry polygenic risk scores in East Asian never-smokers Open
Background Lung adenocarcinoma in never-smokers is a major public health burden, especially among East Asian women. Polygenic risk scores (PRSs) are promising for risk stratification but are primarily developed in European-ancestry populat…
View article: Heavy metals exposure and HPG-axis related hormones in women across the lifespan: An integrative epidemiological and bioinformatic perspective
Heavy metals exposure and HPG-axis related hormones in women across the lifespan: An integrative epidemiological and bioinformatic perspective Open
Our findings highlight the significant associations, folate modifications, and potential pathways of metal exposure on female sex hormones, which provides insights for prevention avenues and mechanisms.
View article: Correction: A novel derivative of betulinic acid, SYK023, suppresses lung cancer growth and malignancy
Correction: A novel derivative of betulinic acid, SYK023, suppresses lung cancer growth and malignancy Open
Correction to: A novel derivative of betulinic acid, SYK023, suppresses lung cancer growth and malignancy
View article: Patritumab Deruxtecan (HER3-DXd; MK-1022) in Non–Small Cell Lung Cancer After Platinum-Based Chemotherapy and Immunotherapy
Patritumab Deruxtecan (HER3-DXd; MK-1022) in Non–Small Cell Lung Cancer After Platinum-Based Chemotherapy and Immunotherapy Open
PURPOSE Patritumab deruxtecan (HER3-DXd; MK-1022) is an investigational HER3-directed antibody-drug conjugate composed of a human immunoglobulin G1 monoclonal antibody to HER3 (patritumab) covalently linked via a stable tetrapeptide-based …
View article: Deubiquitinase USP24 activated by IL-6/STAT3 enhances PD-1 protein stability and suppresses T cell antitumor response
Deubiquitinase USP24 activated by IL-6/STAT3 enhances PD-1 protein stability and suppresses T cell antitumor response Open
Persisting programmed cell death-1 (PD-1) signaling impairs T cell effector function, which is highly associated with T cell exhaustion and immunotherapy failure. However, the mechanism responsible for PD-1 deubiquitination and T cell dysf…
View article: Phase I study of oral metronomic gemcitabine (D07001) in patients with advanced solid tumors
Phase I study of oral metronomic gemcitabine (D07001) in patients with advanced solid tumors Open
Background D07001-F4 is an absorption-enhanced oral gemcitabine developed in liquid formulation and adjusted to D07001-softgel capsules. We conducted 2 phase 1 studies to evaluate the dose-limiting toxicity (DLT), pharmacokinetics (PK), an…
View article: Datopotamab Deruxtecan in Advanced or Metastatic Non–Small Cell Lung Cancer With Actionable Genomic Alterations: Results From the Phase II TROPION-Lung05 Study
Datopotamab Deruxtecan in Advanced or Metastatic Non–Small Cell Lung Cancer With Actionable Genomic Alterations: Results From the Phase II TROPION-Lung05 Study Open
PURPOSE Datopotamab deruxtecan (Dato-DXd) is a trophoblast cell-surface antigen-2–directed antibody-drug conjugate with a highly potent topoisomerase I inhibitor payload. The TROPION-Lung05 phase II trial (ClinicalTrials.gov identifier: NC…
View article: Ultra-short cyclic peptide Cy<sub>RL-QN15</sub> acts as a TLR4 antagonist to expedite oral ulcer healing
Ultra-short cyclic peptide Cy<sub>RL-QN15</sub> acts as a TLR4 antagonist to expedite oral ulcer healing Open
Oral ulcers (OUs) are among the most common lesions of the oral mucosa, typically associated with pain and burning sensations, and remain clinically challenging due to the scarcity of effective treatment options. Cy RL-QN15, a novel ultra-…
View article: Durvalumab, Tremelimumab, and Platinum Chemotherapy in EGFR Mutation–Positive NSCLC: An Open-Label Phase 2 Trial (ILLUMINATE)
Durvalumab, Tremelimumab, and Platinum Chemotherapy in EGFR Mutation–Positive NSCLC: An Open-Label Phase 2 Trial (ILLUMINATE) Open
Durvalumab, tremelimumab, and platinum-pemetrexed had modest anti-tumor activity in EGFR-mutant NSCLC after progression on TKI. The T790M- cohort had higher ORR and a longer duration of response. Immune adverse events were not increased wi…
View article: β-<scp>d</scp>-Ribofuranose as a Core with a Phosphodiester Moiety as the Enzyme Recognition Site for Codrug Development
β-<span>d</span>-Ribofuranose as a Core with a Phosphodiester Moiety as the Enzyme Recognition Site for Codrug Development Open
An ideal codrug design should be able to control drug release, offer selectivity during drug delivery, and break down into non-toxic fragments after biodegradation. Our design incorporates d-ribofuranose as the core, with carbamate and car…
View article: Registry of Genetic Alterations of Taiwan Non–Small Cell Lung Cancer by Comprehensive Next-Generation Sequencing: A Real-World Cohort Study-Taiwan Cooperative Oncology Group T1521
Registry of Genetic Alterations of Taiwan Non–Small Cell Lung Cancer by Comprehensive Next-Generation Sequencing: A Real-World Cohort Study-Taiwan Cooperative Oncology Group T1521 Open
PURPOSE Tissue-based next-generation sequencing (NGS) analysis is highly recommended for patients with advanced/metastatic non–small cell lung cancer (NSCLC). We investigated a specific patient population with NSCLC that required tissue-ba…
View article: Erdafitinib in Asian patients with advanced solid tumors: an open-label, single-arm, phase IIa trial
Erdafitinib in Asian patients with advanced solid tumors: an open-label, single-arm, phase IIa trial Open
Background FGFR genomic aberrations occur in approximately 5–10% of human cancers. Erdafitinib has previously demonstrated efficacy and safety in FGFR -altered advanced solid tumors, such as gliomas, thoracic, gastrointestinal, gynecologic…
View article: Stratifying Lung Adenocarcinoma Risk with Multi-ancestry Polygenic Risk Scores in East Asian Never-Smokers
Stratifying Lung Adenocarcinoma Risk with Multi-ancestry Polygenic Risk Scores in East Asian Never-Smokers Open
Background Lung adenocarcinoma (LUAD) in never-smokers is a major public health burden, especially among East Asian women. Polygenic risk scores (PRSs) are promising for risk stratification but are primarily developed in European-ancestry …
View article: 1MO A phase IIIb study of savolitinib in patients with locally advanced or metastatic NSCLC harboring MET exon 14 mutation
1MO A phase IIIb study of savolitinib in patients with locally advanced or metastatic NSCLC harboring MET exon 14 mutation Open
Savolitinib is a potent and highly selective oral MET tyrosine-kinase inhibitor, approved in China for the treatment of NSCLC patients (pts) that have progressed following prior systemic therapy or are unable to receive chemotherapy with M…
View article: Polygenic Risk Score, Environmental Tobacco Smoke, and Risk of Lung Adenocarcinoma in Never-Smoking Women in Taiwan
Polygenic Risk Score, Environmental Tobacco Smoke, and Risk of Lung Adenocarcinoma in Never-Smoking Women in Taiwan Open
Importance Estimating absolute risk of lung cancer for never-smoking individuals is important to inform lung cancer screening programs. Objectives To integrate data on environmental tobacco smoke (ETS), a known lung cancer risk factor, wit…
View article: Clinical implications of PNA‑sequencing as a complementary test for EGFR mutation analysis in human lung cancer
Clinical implications of PNA‑sequencing as a complementary test for EGFR mutation analysis in human lung cancer Open
Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are the first-line regimen for the treatment of non-small cell lung cancer (NSCLC) patients with EGFR mutations. However, false-negative results are occasionally obser…